Privately-owned NovImmune SA of Geneva, Switzerland has raised an additional CHF 20 million (€15.7 million) from a syndicate led by BZ Bank Aktiengesellschaft to advance its monoclonal antibody development programmes. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
